Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Get To Be familiar with The Historical backdrop Of Western Medication - 2Miss Thailand Pageant Contestant's Veneers Fall Out During Speech on Stage
- 310 Work Valuable chances to Assist with supporting Your Advanced degree
- 4The Job of a Migration Legal advisor: How They Can Help You
- 5Flying without a Real ID? That'll soon cost you $45, TSA says.
- Africa's energy giants eye long-term gains on Iran war disruption
- How did Ariana Grande get her Glinda voice? I’m the man behind the magic.
- A few Up-to-date Sacks - Stylish Young ladies Shouldn't Miss
- Share your pick for the tree that you love for its novel magnificence!
- Over 1,800 killed since junta seized power in Burkina Faso, rights group says
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- How color-changing, bacteria-infused spacesuits could help keep future astronauts safe from space radiation
- Must-See Public Parks from Around the Globe
- Vaccine exemptions for religious or personal beliefs are rising across the U.S.
